Magnetar Financial LLC Blueprint Medicines Corp Transaction History

Magnetar Financial LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$37.97 - $50.0 $70,700 - $93,100	-1,862 Reduced 16.73%	9,266 $416,000
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $456,915 - $739,789	11,128 New	11,128 $488,000
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $623,314 - $966,737	-13,781 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $745,552 - $1.52 Million	13,781 New	13,781 $880,000
Q3 2021 Nov 12, 2021	SELL	$80.98 - $109.47 $522,644 - $706,519	-6,454 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$82.78 - $101.0 $534,262 - $651,854	6,454 New	6,454 $568,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Magnetar Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Magnetar Financial LLC with notifications on news.